Specialist reinsurance broker BMS Group has appointed Jean-Jacques Henchoz as its board chairman, with the role to be handed ...

The deal – which could be worth up to $2.2 billion if PRX005 reaches the market – comes nearly a decade after BMS all-but exited the category after abandoning amyloid-targeting drug avagacestat.

BMS Group, an independent specialist insurance and reinsurance broker, has appointed Jean-Jacques Henchoz, who recently left ...

The Fidelis Partnership (TFP) a privately owned, Bermuda-domiciled managing general underwriter, has appointed reinsurance and insurance-linked securities ...

BMS Group has announced Jean-Jaques Henchoz as the new chairman of its board, the latest appointment for the executive following his departure from Hannover Re. He will assume the position at the ...

Broker appoints veteran reinsurance leader Jean-Jacques Henchoz, previously CEO and chairman of the executive board at ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

Make sure you're protected! Insure your Utility Vehicles for as low as just $75/year.* Insure your 2018 BMS Motorsports for just $75/year.* Savings: We offer low rates and plenty of discounts. More ...